Currently set to Index
Currently set to Follow
PROFILE
search
ask age2b
CART

Improved glycemic control in 3,592 adults with type 2 diabetes mellitus initiating a tubeless insulin management system

By AGE2B team
November 7, 2021
0
0

Main idea: Omnipod System use was associated with statistically and clinically meaningful reductions in Hemoglobin A1c(HbA1c)e A1c(HbA1c), TDD, and HE compared to prior treatments in T2DM.

Abstract

To compare glycemic outcomes in adults with type 2 diabetes mellitus (T2DM) before and 90 days after initiating Omnipod® or Omnipod DASH® Insulin Management Systems.

In this retrospective observational study (N = 3,592) the change in Hemoglobin A1c(HbA1c)e A1c(HbA1c) level, total daily dose (TDD) of insulin (n = 3,053), and frequency of self-reported hypoglycemic events (HE, <70 mg/dL, n = 2,922) were assessed overall and by prior treatment modality (multiple daily injections (MDI) or continuous subcutaneous insulin infusion (CSII)), age group, and baseline Hemoglobin A1c(HbA1c)e A1c(HbA1c) category.

Source DRCP

Leave a Reply

Ask your question

We read all your emails and your text. Your question will be responded by our specialists, or one of the doctors we're working with, or our community

Please complete the required fields.